Aptevo Therapeutics (APVO) Leases (2019 - 2025)
Aptevo Therapeutics (APVO) has disclosed Leases for 7 consecutive years, with $4.0 million as the latest value for Q3 2025.
- Quarterly Leases fell 12.32% to $4.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Sep 2025, down 12.32% year-over-year, with the annual reading at $4.4 million for FY2024, 10.08% down from the prior year.
- Leases hit $4.0 million in Q3 2025 for Aptevo Therapeutics, down from $4.1 million in the prior quarter.
- In the past five years, Leases ranged from a high of $5.5 million in Q2 2022 to a low of $1.3 million in Q1 2022.
- Historically, Leases has averaged $4.0 million across 5 years, with a median of $4.5 million in 2024.
- Biggest five-year swings in Leases: plummeted 46.58% in 2022 and later soared 298.16% in 2023.
- Year by year, Leases stood at $1.6 million in 2021, then soared by 234.79% to $5.3 million in 2022, then fell by 7.96% to $4.9 million in 2023, then decreased by 10.08% to $4.4 million in 2024, then decreased by 9.71% to $4.0 million in 2025.
- Business Quant data shows Leases for APVO at $4.0 million in Q3 2025, $4.1 million in Q2 2025, and $4.3 million in Q1 2025.